Skip to main content

Advertisement

SpringerLink
Log in

Diffuse lewy body disease

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

  • •Diffuse Lewy body disease (DLB) is a neurodegenerative disorder characterized by dementia, fluctuations in mental status, hallucinations, and parkinsonism. Diffuse Lewy body disease is the second most common cause of dementia, following Alzheimer’s disease. The treatment of DLB includes cholinergic therapy for cognitive impairment, atypical neuroleptics to alleviate hallucinations, and levodopa/carbidopa to improve parkinsonism.

  • •The recognition and diagnosis of DLB has critical treatment implications.

  • •Centrally acting cholinesterase inhibitors, such as rivastigmine, donepezil, and galantamine partially reverse decreased cortical cholinergic activity and may improve cognition and neuropsychiatric symptoms in DLB. Rivastigmine has been demonstrated to improve cognition and neuropsychiatric symptoms in patients with DLB without worsening parkinsonian features. Due to the potential adverse events associated with neuroleptics in this population, treatment with cholinesterase inhibitors is currently considered first-line therapy in the treatment of hallucinations and mental status fluctuations in DLB.

  • •Exquisite sensitivity to neuroleptic medications is a hallmark of DLB and lifethreatening complications have been reported. Caution should be exercised when implementing antipsychotic therapy for the treatment of behavioral disturbances of DLB. When required, atypical neuroleptics with the least extrapyramdial side effects, such as quetiapine, should be used.

  • •The parkinsonian features of DLB may respond to dopaminergic therapy with levodopa. If parkinsonian symptoms result in clinical disability, a trial of levodopa is warranted. Unfortunately, dopaminergic medications may worsen hallucinations. Because dopamine agonists have a greater tendency to induce hallucinations and somnolence, levodopa is the treatment of choice for parkinsonism in DLB.

  • •Rapid eye movement (REM) sleep behavior disorder (RBD) is now recognized as a feature of DLB. Awareness of the presence of this symptom in patients with DLB is important and treatment with low dose clonazepam may help. Cholinergic aumentation may also improve these symptoms in patients with DLB.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References and Recommended Reading

  1. Parkinson J: An Essay on the Shaking Palsy. London: Sherwood, Neely & Jones; 1817:66.

    Google Scholar 

  2. McKeith IG, Perry EK, Perry RH: Diagnosis and treatment of dementia with Lewy bodies (DLB): report of the second DLB International Workshop. Neurology 1999, 53:902–905. A good article on Lewy body disease.

    PubMed  CAS  Google Scholar 

  3. Weiner MF, Risser RC, Cullum CM, et al.: Alzheimer’s disease and its Lewy body variant: a clinical analysis of post-mortem verified cases. Am J Psychiatry 1996, 143:1269–1273.

    Google Scholar 

  4. Lewy FH: Paralysis agitans, I: pathologische anatomie. In Handbuch der Neurologie. Edited by Lewandowsky M. Berlin: Springer; 1912:920–933.

    Google Scholar 

  5. Okazaki H, Lipkin LE, Aronson SM: Diffuse intracytoplasmic ganglionic inclusions (Lewy type) associated with progressive dementia and quadriparesis in flexion. J Neuropathol Exp Neurol 1961, 20:237.

    PubMed  CAS  Google Scholar 

  6. Kosaka K, Matsushita M, Oyanagi S, et al.: A clinicopathological study of the "Lewy body disease." Psychiatr Neurol Jpn 1980, 82:292–311.

    CAS  Google Scholar 

  7. Polymeropoulos MH, Lavedan C, Leroy E, et al.: Mutation in the alpha-synuclein gene identified in families with Parkinson’s disease. Nat Genet 1997, 276:2045–2047.

    CAS  Google Scholar 

  8. Spillantini MG, Crowther RA, Jakes R, et al.: Alphasynuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with Lewy bodies. Proc Natl Acad Sci 1998, 95:6469–6473.

    Article  PubMed  CAS  Google Scholar 

  9. Galvin JE, Lee MYL, Trojanowski JQ: Synucleinopathies. Arch Neurol 2001, 58:186–190. Concise review of the synucleinopathies.

    Article  PubMed  CAS  Google Scholar 

  10. McKeith IG, O’Brien JT, Ballard C: Diagnosing dementia with Lewy bodies. Lancet 1999, 354:1227–1228.

    Article  PubMed  CAS  Google Scholar 

  11. Mega MS, Masterman DL, Benson F, et al.: Dementia with Lewy bodies: reliability and validity of clinical and pathological criteria. Neurology 1996, 47:1403–1409.

    PubMed  CAS  Google Scholar 

  12. Luis CA, Barker WW, Gajara K, et al.: Sensitivity and specificity of three clinical criteria for dementia with Lewy bodies in an autopsy-verified sample. Int J Geriatr Psychiatry 1999, 14:526–523.

    Article  PubMed  CAS  Google Scholar 

  13. Holmes C, Cairns N, Lantos P, Mann A: Validity of current clinical criteria for Alzheimer’s disease, vascular dementia, and dementia with Lewy bodies. Br J Psychiatry 1999, 174:45–50.

    PubMed  CAS  Google Scholar 

  14. Verghese J, Crystal HA, Dickson DW, Lipton RB: Validity of clinical criteria for the diagnosis of dementia with Lewy bodies. Neurology 1999, 53:1974–1982.

    PubMed  CAS  Google Scholar 

  15. McKeith IG, Grace JB, Walker Z, et al.: Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 2000, 15:387–392.

    Article  PubMed  CAS  Google Scholar 

  16. Byrne EJ, Lennox G, Lowe J, Reynolds G: Diffuse Lewy body disease: the clinical features. Adv Neurol 1990, 53:283–286.

    PubMed  CAS  Google Scholar 

  17. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975, 12:189.

    Article  PubMed  CAS  Google Scholar 

  18. McKeith IG, Galasko D, Kosaka K, et al.: Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996, 47:1113–1124.

    PubMed  CAS  Google Scholar 

  19. Sahgal A, Galloway PH, McKeith IG, et al.: A comparative study of attentional deficits in senile dementias of Alzheimer and Lewy body types. Dementia 1992, 3:350–354.

    Google Scholar 

  20. Del-Ser T, Munoz DG, Hachinski V: Temporal pattern of cognitive decline and incontinence is different in Alzheimer’s disease and diffuse Lewy body disease. Neurology 1996, 46:682–686.

    PubMed  CAS  Google Scholar 

  21. O’Donnell BF, Drachman DA, Barnes HJ, et al.: Incontinence and troublesome behavior predict institutionalization in dementia. J Geriatr Psychiatry Neurol 1992, 5:45–52.

    PubMed  CAS  Google Scholar 

  22. Walker MP, Ayre GA, Cummings JL, et al.: Quantifying fluctuations in dementia associated with Lewy bodies, Alzheimer’s disease and vascular dementia. Neurology 2000, 54:1616–1624.

    PubMed  CAS  Google Scholar 

  23. Briel RCG, McKeith IG, Barker WA, et al.: EEG findings in dementia with Lewy bodies and Alzheimer’s disease. J Neurol Neurosurg Psychiatr 1999, 66:401–403.

    Article  PubMed  CAS  Google Scholar 

  24. Klatka LA, Louis ED, Schiffer RB: Psychiatric features in diffuse Lewy body disease: a clinicopathologic study using Alzheimer’s disease and Parkinson’s disease comparison groups. Neurology 1996, 47:1148–1152.

    PubMed  CAS  Google Scholar 

  25. Ballard C, Holmes C, McKeith I, et al.: Psychiatric morbidity in dementia with Lewy bodies: a prospective clinical and neuropathological comparative study with Alzheimer’s disease. Am J Psychiatry 1999, 156:66–72.

    Google Scholar 

  26. Louis ED, Goldman JE, Powers JM, Fahn S: Parkinsonian features of eight pathologically diagnosed cases of diffuse Lewy body disease. Mov Disord 1995, 10:188–194.

    Article  PubMed  CAS  Google Scholar 

  27. Louis ED, Klatka LA, Liu Y, Fahn S: Comparison of extrapyramidal features in 31 pathologically confirmed cases of diffuse Lewy body disease and 34 pathologically confirmed cases of Parkinson’s disease. Neurology 1997, 48:376–380.

    PubMed  CAS  Google Scholar 

  28. Burkhardt CR, Filley CM, Kleinschmidt-DeMasters BK, et al.: Diffuse Lewy body disease and progressive dementia. Neurology 1998, 38:1520–1528.

    Google Scholar 

  29. Hurtig HI, Trojanowski JQ, Galvin J, et al.: Alphasynuclein cortical Lewy bodies correlate with dementia in Parkinson’s disease. Neurology 2000, 54:1916–1921.

    PubMed  CAS  Google Scholar 

  30. Louis ED, Fahn S: Pathologically diagnosed diffuse Lewy body disease: do the Parkinsonian features differ? Adv Neurol 1996, 69:311–314.

    PubMed  CAS  Google Scholar 

  31. Haïk S, Brandel JP, Saxdovitch V, et al.: Dementia with Lewy bodies in a neuropathological series of suspected Creutzfeldt-Jakob disease. Neurology 2000, 55:1401–1404.

    PubMed  Google Scholar 

  32. McKeith IG, Fairbain A, Perry R, et al.: Neuroleptic sensitivity in patients with senile dementia of the Lewy body type. BMJ 1992, 35:673–678.

    Google Scholar 

  33. Ballard C, Grace J, McKeith I, Holmes C: Neuroleptic sensitivity in dementia with Lewy bodies and Alzheimer’s disease. Lancet 1998, 351:1032–1033.

    Article  PubMed  CAS  Google Scholar 

  34. McKeith IG, Ballard CG, Harrison RWS: Neuroleptic sensitivity to risperidone in Lewy body dementia. Lancet 1995, 346:699.

    Article  PubMed  CAS  Google Scholar 

  35. Walker Z, Grace J, Overshot R, et al.: Olanzapine in dementia with Lewy bodies: a clinical study. Int J Geriatr Psychiatr 1999, 14:459–456.

    Article  CAS  Google Scholar 

  36. Piggott MA, Perry EK, McKeith IG, et al.: Dopamine D2 receptors in demented patients with severe neuroleptic sensitivity. Lancet 1994, 343:1044–1045.

    Article  PubMed  CAS  Google Scholar 

  37. Bashir K, Elble RJ, Ghobrial M, Struble RG: Hemianopsia in dementia with Lewy bodies. Arch Neurol 1998, 55:1132–1135.

    Article  PubMed  CAS  Google Scholar 

  38. Hauser RA, Gauger L, Anderson WM, Zesiewicz TA: Pramipexole-induced somnolence and episodes of daytime sleep. Mov Disord 2000, 15:658–663. An excellent, important paper.

    Article  PubMed  CAS  Google Scholar 

  39. Ferman TJ, Boeve BF, Smith GE: REM sleep behavior disorder and dementia: cognitive differences when compared to Alzheimer’s disease. Neurology 1999, 52:951–957.

    PubMed  CAS  Google Scholar 

  40. Schenk CH, Bundlie SR, Mahowald MW: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder. Neurology 1996, 46:388–393.

    Google Scholar 

  41. Boeve BF, Silber MH, Ferman TJ, et al.: REM sleep behavior disorder and degenerative dementia: an association likely reflecting Lewy body disease. Neurology 1998, 51:363–370.

    PubMed  CAS  Google Scholar 

  42. Turner RS, Amato CJD, Chervin RD, Blaivas M: The pathology of REM sleep behavior disorder with comorbid Lewy body dementia. Neurology 2000, 55:1730–1732.

    PubMed  CAS  Google Scholar 

  43. Ringman JM, Simmons JH: Treatment of REM sleep behavior disorder with donepezil: a report of three cases. Neurology 2000, 55:870–871.

    PubMed  CAS  Google Scholar 

  44. Kuzuhara S, Yoshimura M: Clinical and neuropathological aspects of diffuse Lewy body disease in the elderly. Adv Neurol 1993, 60:464–469.

    PubMed  CAS  Google Scholar 

  45. George JM, Jin H, Woods WS, Clayton DF: Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 1995, 15:361–372.

    Article  PubMed  CAS  Google Scholar 

  46. Iseki E, Marui W, Kosaka K, et al.: Degenerative terminals of the perforant pathway are human-α-synuclein-immunoreactivity in the hippocampus of patients with diffuse Lewy body disease. Neurosci Lett 1998, 258:81–84.

    Article  PubMed  CAS  Google Scholar 

  47. Masliah E, Rockenstein E, Veinbergs I, et al.: Dopaminergic loss and inclusion body formation in α-synuclein mice: implications for neurodegenerative disorders. Science 2000, 287:1265–1269.

    Article  PubMed  CAS  Google Scholar 

  48. Kahle PJ, Neumann M, Ozmen L, Haass C: Physiology and pathophysiology of _-synuclein: cell culture and transgenic animal models based on a Parkinson’s disease-associated protein. Ann N Y Acad Sci 2000, 920:33–38.

    Article  PubMed  CAS  Google Scholar 

  49. McGreer PL, Itagaki S, Tago H, McGeer EG: Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatiblity glycoprotein HLA-DR. Neurosci Lett 1987, 79:1995–200.

    Google Scholar 

  50. McKenzie IRA: Activated microglia in dementia with Lewy bodies. Neurology 2000, 55:132–134.

    Google Scholar 

  51. Shepherd CE, Thiel E, McCann H, et al.: Cortical inflammation in Alheimer’s disease but not dementia with Lewy bodies. Arch Neurol 2000, 57:817–822.

    Article  PubMed  CAS  Google Scholar 

  52. Perry EK, McKeith I, Thompsom P, et al.: Topograpy, extent, and clinical relevance of neurochemical deficits in dementia of Lewy body type, Parkinson’s disease, and Alzheimer’s disease. Ann N Y Acad Sci 1991, 640:197–202.

    PubMed  CAS  Google Scholar 

  53. Shiozaki K, Iseki E, Uchiyama H, et al.: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease. J Neurol Neurosurg Psychiatry 1999, 67:209–213.

    PubMed  CAS  Google Scholar 

  54. Jellinger K: Alterations of muscarinic acetylcholine receptor subtypes in diffuse Lewy body disease: relation to Alzheimer’s disease [letter]. J Neurol Neurosurg Psychiatry 2000, 68:243–254.

    Article  Google Scholar 

  55. Tiraboschi P, Hansen LA, Alford M, et al.: Cholinergic dysfunction in diseases with Lewy bodies. Neurology 2000, 54:407–411.

    PubMed  CAS  Google Scholar 

  56. Ohara K, Kondo N, Ohara K: Changes of monoamines in post-mortem brains from patients with diffuse Lewy body disease. Prog Neuro Biol Psychiatry 1998, 22:311–317.

    Article  CAS  Google Scholar 

  57. Piggott MA, Marshall EF, Thomas N, et al.: Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s disease and Parkinson’s disease: rostrocaudal distribution. Brain 1999, 122:1449–1468.

    Article  PubMed  Google Scholar 

  58. Barber R, Scheltens P, Gholkar A, et al.: White matter lesions on magnetic resonance imaging in dementia with Lewy bodies, Alzheimer’s disease, vascular dementia, and normal aging. J Neurol Neurosurg Psychiatr 1999, 67:66–72.

    PubMed  CAS  Google Scholar 

  59. Higuchi M, Tashiro M, Arai H, et al.: Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies. Exp Neurol 2000, 162:247–256.

    Article  PubMed  CAS  Google Scholar 

  60. Albin RL, Minoshima S, D’Amato CJ, et al.: Fluorodeoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology 1996, 47:462–466.

    PubMed  CAS  Google Scholar 

  61. Hu XS, Okamura N, Arai H, et al.: 18F-Fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies. Neurology 2000, 55:1575–1577.

    PubMed  CAS  Google Scholar 

  62. Bohnen NI, Minoshima S, Giordani B, et al.: Motor correlates of occipital glucose hypometabolism in Parkinson’s disease without dementia. Neurology 1999, 52:541.

    PubMed  CAS  Google Scholar 

  63. Talbot PR, Loyd JJ, Snowden JS, et al.: A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 1998, 64:306–313.

    PubMed  CAS  Google Scholar 

  64. Ishii K, Yamaji S, Kitagaki H, et al.: Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology 1999, 53:413–416.

    PubMed  CAS  Google Scholar 

  65. Lobotesis K, Fenwick JD, Phipps A, et al.: Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 2001, 56:643–649.

    PubMed  CAS  Google Scholar 

  66. Shea C, MacKnight C, Rockwood K: Donepezil for treatment of dementia with Lewy bodies: a case series of nine patients. Int Psychogeriatr 1998, 10:229–238.

    Article  PubMed  CAS  Google Scholar 

  67. Kaufer DI, Catt KE, Lopez OL, DeKosky ST: Dementia with Lewy bodies: response to delerium-like features to donepezil. Neurology 1998, 51:1512.

    PubMed  CAS  Google Scholar 

  68. Lebert F, Pasquier F, Souliez L: Tacrine efficacy in Lewy body dementia. Int J Geriatr Psychiatry 1998, 13:516–519.

    Article  PubMed  CAS  Google Scholar 

  69. Levy R, Eagger S, Griffiths M, et al.: Lewy bodies and response to tacrine in Alzheimer’s disease. Lancet 1994, 343:176.

    Article  PubMed  CAS  Google Scholar 

  70. Wilcox GK, Scott MI: Tacrine for senile dementia of Alzheimer’s of Lewy body type. Lancet 1994, 344:544.

    Article  Google Scholar 

  71. McKeith I, Del Set T, Spano P, et al.: Efficacy of rivastigmine in dementia with Lewy body: a randomized, double-blind, placebo-controlled international study. Lancet 2000, 356:2031–2036. An important study that examines treatment with rivastigmine in Lewy body dementia.

    Article  PubMed  CAS  Google Scholar 

  72. Samuel W, Caligirui M, Galasko D, et al.: Better cognitive performance and psychopathological response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int J Geriatr Psychiatry 2000, 15:794–802.

    Article  PubMed  CAS  Google Scholar 

  73. Lanctot KL, Hermann N: Donepezil for behavioural disorders associated with Lewy bodies: a case series. Int J Geriatr Psychiatry 2000, 15:338–345.

    Article  PubMed  CAS  Google Scholar 

  74. Querfurth HW, Allam GJ, Geffroy MA, et al.: Acetylcholinesterase inhibitors in dementia with Lewy bodies: results of a prospective pilot study. Dementia Geriatr Cogn Disord 2000, 11:314–321.

    Article  CAS  Google Scholar 

  75. Olson EJ, Boeve BF, Silber MH: Rapid eye movement sleep behavior disorder: demographic, clinical, and laboratory findings in 93 cases. Brain 2000, 123:331–339.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Parkinson’s Disease and Movement Disorders Center, University of South Florida, 4 Columbus Drive, South, Suite 410, 33606, Tampa, FL, USA

    Robert A. Hauser MD, MBA

Authors
  1. Theresa A. Zesiewicz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J. Baker MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Peter B. Dunne MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert A. Hauser MD, MBA
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zesiewicz, T.A., Baker, M.J., Dunne, P.B. et al. Diffuse lewy body disease. Curr Treat Options Neurol 3, 507–518 (2001). https://doi.org/10.1007/s11940-001-0013-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-001-0013-x

Keywords

Search

Navigation